In this retrospective analysis, researchers aimed to evaluate outcomes of continuing next-generation ALK TKIs plus chemotherapy after progression on TKI monotherapy in patients with ALK-positive NSCLC ...

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...

Researchers in Houston analyzed the locations of 114 proposed industrial projects related to oil and gas in Texas, most of ...

At a time of heightened concerns for the future of free speech, Florida State University researchers warn of a “troubling ...

In a controlled study, researchers used DMT and watched adults' brain activity change as their usual "sense of self" slipped ...

Despite decades of poor performances, the Photo City Browns Backers continue to meet up each week to cheer on the Cleveland ...

With the holiday shopping season well under full swing, consumers are seeking ways to get the most out of the deals retailers ...

VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...

Epkinly plus rituximab and lenalidomide is the first bispecific antibody combination FDA-approved for relapsed or refractory follicular lymphoma, backed by Phase III data showing substantially ...

This week’s SEO Pulse examines new data what drives AI citations, plus ChatGPT launches shopping research. Your quick catch-up on what practitioners need to know.

Also: Christmas parade enjoyed by many; fun things to do; 123 voters turned away from the polls for not being able to prove ...

Millions face Medicare decisions each year, but many don’t take advantage of tools that can save them money and stress.